Hugh M. Davis

CIK: 0002045027

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRS

Aclaris Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Exercise(M)
Direct
18.7K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
336.3K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Units
Direct
96.1K shares-
ACRS
Aclaris Therapeutics, Inc.
Dec 2, 2025
Exercise(M)
Direct
26.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
261.6K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Restricted Stock Units
Direct
74.7K shares-
ACRS
Aclaris Therapeutics, Inc.
Dec 2, 2024
Award(A)
Employee Stock Option (Right to Buy)
Direct
375K shares-
ACRS
Aclaris Therapeutics, Inc.
Dec 2, 2024
Award(A)
Restricted Stock Units
Direct
107K shares-

		Type	Shares	Price		Ownership
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	18,675	-	$0	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	336,300	-	-	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	96,100	-	-	Direct
Dec 2, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	26,750	-	-	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	261,600	-	-	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	74,700	-	-	Direct
Dec 2, 2024	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	375,000	-	-	Direct
Dec 2, 2024	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	107,000	-	-	Direct

1-8 of 8 transactions

About Davis Hugh M.

Davis Hugh M. (SEC CIK 0002045027) files insider reports with the SEC as President and COO of Aclaris Therapeutics, Inc. (ACRS).

Signal8 holds 6 ownership filings by Davis Hugh M. (1 Form 3, 5 Form 4), filed between Nov 18, 2024 and Feb 6, 2026. Those filings report 8 transactions, from Dec 2, 2024 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Davis Hugh M.'s filings is in WAYNE, PA.

Recent filings by Davis Hugh M.

Feb 3, 2026: Option exercise of ACRS shares (Form 4, code M).
Feb 2, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
Dec 2, 2025: Option exercise of ACRS shares (Form 4, code M).
Feb 3, 2025: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
Dec 2, 2024: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).

Other insiders filing for Aclaris Therapeutics, Inc. (ACRS)

Kolbeck Roland Wilhelm, Chief Scientific Officer
SCHIFF ANDREW N, Director
Mehra Anand, Director
Molineaux Christopher P., Director
Humphries William D., Director
MILANO VINCENT, Director

How to read Form 4 transaction codes